Vitalize trial: A phase 2b, open-label, multicenter, randomized parallel-group, two-stage, study of the novel immunotherapeutic, maveropepimut-S, and pembrolizumab with and without intermittent low-dose cyclophosphamide, in subjects with relapsed/refractory diffuse large B-cell lymphoma Meeting Abstract
| Authors: | Matasar, M. J.; Lee, E.; Leitch, S.; Solh, M.; Teti, J.; Mody, K.; Fiset, S.; Graff, J. |
| Abstract Title: | Vitalize trial: A phase 2b, open-label, multicenter, randomized parallel-group, two-stage, study of the novel immunotherapeutic, maveropepimut-S, and pembrolizumab with and without intermittent low-dose cyclophosphamide, in subjects with relapsed/refractory diffuse large B-cell lymphoma |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 12073 |
| End Page: | 12074 |
| Language: | English |
| ACCESSION: | WOS:000893230305048 |
| DOI: | 10.1182/blood-2022-159000 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
